CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma subjects with a methylated O6‐methylguanine‐deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor tissue. The gene discussed is MGMT; the disease is glioblastoma.